Hideki Shimodaira
Affiliations: | Tohoku University School of Medicine, Japan |
Google:
"Hideki Shimodaira"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Shimodaira H. (2019) Interpreting variants of uncertain significance in hereditary cancer genes in cancer genome era Annals of Oncology. 30: vi4 |
| Oishi T, Sato K, Morita T, et al. (2018) Patient perceptions of curability and physician-reported disclosures of incurability in Japanese patients with unresectable/recurrent cancer: a cross-sectional survey. Japanese Journal of Clinical Oncology |
| Kato S, Imai H, Gamoh M, et al. (2018) Intermittent Withdrawal of Oxaliplatin for Alleviating Neurotoxicity during Oxaliplatin-Based Chemotherapy for Japanese Patients with Inoperable or Metastatic Colorectal Cancer: A Phase 2 Multicenter Study. The Tohoku Journal of Experimental Medicine. 245: 21-28 |
| Makiyama A, Kunieda K, Noguchi M, et al. (2018) First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study. Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association |
| Bando H, Shimodaira H, Fujitani K, et al. (2018) A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer. European Journal of Cancer (Oxford, England : 1990). 91: 86-91 |
| Takahashi M, Gamoh M, Ohori H, et al. (2018) Possible predictive value of G8 score and the drug concentrations for efficacy and toxicity of trifluridine/tipiracil for elderly patients with advanced colorectal cancer: A multicenter, phase II study (T-CORE1401). Journal of Clinical Oncology. 36 |
| Takashima A, Bando H, Shimodaira H, et al. (2018) A phase II study of nab-PTX in combination with RAM in patients with pre-treated AGC: results of final analysis. Annals of Oncology. 29 |
| Yamada Y, Denda T, Gamoh M, et al. (2017) S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase 3, non-inferiority trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology |
| Takahashi H, Takahashi M, Ohnuma S, et al. (2017) microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer. Bmc Cancer. 17: 723 |
| Horie S, Oya M, Nangaku M, et al. (2017) Guidelines for treatment of renal injury during cancer chemotherapy 2016. Clinical and Experimental Nephrology |